Several studies have also suggested that HDACIs could enhance the effect of EGFR inhibitors in NSCLC by repressing the expression or phosphorylation of EGFR, HER2, c-MET, AXL, and IGF1R 17-19. The gene discussed is MET; the disease is non-small cell lung carcinoma.